SRR598638
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INFLAMMATORY_RESPONSE+0.376
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.337
- COAGULATION+0.324
- KRAS_SIGNALING_DN+0.297
- MYOGENESIS+0.285
- ALLOGRAFT_REJECTION+0.281
- ESTROGEN_RESPONSE_LATE+0.268
- KRAS_SIGNALING_UP+0.263
- COMPLEMENT+0.258
- ANGIOGENESIS+0.257
Top 10 suppressed
- MYC_TARGETS_V2-0.558
- DNA_REPAIR-0.501
- MYC_TARGETS_V1-0.486
- OXIDATIVE_PHOSPHORYLATION-0.411
- E2F_TARGETS-0.402
- PROTEIN_SECRETION-0.382
- G2M_CHECKPOINT-0.355
- UNFOLDED_PROTEIN_RESPONSE-0.347
- CHOLESTEROL_HOMEOSTASIS-0.323
- NOTCH_SIGNALING-0.292
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR600533 | GTEX | — | 0.973 |
| 2 | SRR615096 | GTEX | — | 0.929 |
| 3 | SRR1319136 | GTEX | — | 0.928 |
| 4 | SRR1389059 | GTEX | — | 0.927 |
| 5 | SRR602622 | GTEX | — | 0.927 |
| 6 | MDT-AP-0567 | Med | Medulloblastoma | 0.925 |
| 7 | SRR598124 | GTEX | — | 0.924 |
| 8 | SRR602839 | GTEX | — | 0.923 |
| 9 | SRR817856 | GTEX | — | 0.920 |
| 10 | SRR1366961 | GTEX | — | 0.920 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.376 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.337 | Inavolisib | — uncovered |
| COAGULATION | 0.324 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.297 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.285 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.281 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.268 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.263 | Inavolisib | — uncovered |
| COMPLEMENT | 0.258 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.257 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.242 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.235 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.231 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.216 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.192 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.189 | Cobimetinib | — uncovered |
| HYPOXIA | 0.179 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.147 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.136 | Inavolisib | — uncovered |